Fig. 6
From: FBXO22 targets ubiquitination and degradation of c-Cbl in leukemia

Effects of FBXO22 overexpression and c-Cbl knockdown on leukemia progression in vivo. (A-B, E-F) Reduced tumor metastases and sizes in treatment groups. (C-D, G-H) Decreased liver and spleen weights. Data are shown as the mean ± SD of three independent experiments. *p < 0.05 compared to EV, #p < 0.05 compared to NC, ##p < 0.01 compared to NC. (I) HE staining showing reduced U937 cell infiltration in spleen. (J) c-Cbl downregulation in FBXO22-overexpressing tumors. (K-L) Increased CD11b expression by Western blot and IHC.